Easing Digestive Discomfort and Nausea

Omidon is used to address distressing symptoms associated with upper gastrointestinal function, specifically nausea and vomiting. It is used to provide relief in situations involving acute or unstable symptom patterns. This support helps to reduce the overall symptom load and assists in maintaining functional stability during periods of increased physical discomfort.

Supportive Relief for Episodic Symptoms

This medicine is relevant for managing symptom clusters that interfere with daily comfort. It is commonly used when short-term symptomatic assistance is required for digestive distress. By providing targeted relief, it helps in managing episodic symptoms more effectively.

Quick Fact: Relevant for Episodic Symptoms Omidon is used in scenarios where additional management of discomfort is required, especially during periods when symptoms of nausea or vomiting become more noticeable.

Regulatory References

1. EMA Domperidone Referral Overview

Eligibility Map: Who can and cannot use Omidon — Official Regulatory Information

The official eligibility for Omidon is strictly defined by regulatory bodies (EMA, national health authorities) primarily to manage cardiovascular risk.

Eligibility Scope

Age and Condition-Specific Rules

• Older adults (aged >60 years) are at a higher risk and require the lowest effective dose for the shortest duration.
• Use is prohibited when gastrointestinal motility stimulation could be harmful (e.g., GI hemorrhage or obstruction).
• For patients with severe renal impairment, the administration frequency must be reduced.

Connection to the overall eligibility profile

Regulatory documents establish absolute contraindications based on critical factors like pre-existing heart conditions and severe liver impairment, defining who must not use the medicine. Eligibility is conditional or restricted for older adults and those with severe kidney impairment, while use is formally not recommended for the youngest populations and for women who are pregnant or breastfeeding.

Omidon (domperidone) can interact with several other medicines and substances, potentially increasing the risk of serious side effects, particularly those affecting heart rhythm (QTc prolongation). The following are important interactions to be aware of:

Contraindicated Combinations

Strong CYP3A4 Inhibitors and QTc-Prolonging Drugs

Omidon is primarily metabolized by the CYP3A4 enzyme. Co-administration with medicines that strongly inhibit this enzyme can significantly increase Omidon's concentration in the blood, heightening the risk of heart problems. It is contraindicated to use Omidon with potent CYP3A4 inhibitors and/or medicines known to prolong the QTc interval. These include, but are not limited to:

Other Notable Interactions

• Anticholinergics: Drugs with anticholinergic properties can counteract Omidon's effect on gastrointestinal movement.
• Antacids and Anti-Secretory Drugs: These should not be taken simultaneously with Omidon as they can reduce its absorption and effectiveness.
• Dopamine Agonists (e.g., Bromocriptine, L-dopa): Omidon can suppress the unwanted peripheral side effects (like nausea and vomiting) of these agents without counteracting their central effects.
• Food and Drink: Taking Omidon with food can delay its absorption. Grapefruit juice should be avoided as it can inhibit CYP3A4, leading to increased Omidon levels.

Always inform your healthcare provider about all medicines, over-the-counter products, and herbal supplements you are taking to ensure safe use.

Omidon functions as a selective, small-molecule inhibitor of the cyclooxygenase-2 ( COX-2) enzyme. Following systemic absorption, Omidon achieves high concentration at sites of COX-2 expression, including local tissue. The drug engages the active site of the COX-2 enzyme, forming a reversible interaction that competitively blocks the catalytic activity. This inhibition prevents the conversion of its substrate, arachidonic acid, into prostaglandin H2 ( PGH2). This enzymatic blockade results in a significant reduction in the synthesis of downstream pro-inflammatory prostaglandins, such as PGE2 and prostacyclin. The reduction in these local lipid mediators modulates the overall inflammatory signaling cascade and alters cellular responses mediated by these eicosanoids, representing a physiological modification of the body’s signaling pathways.

Omidon, containing the active substance Domperidone, is administered primarily via the oral route as tablets or a liquid suspension, with suppositories available for rectal use. The official instructions for administration emphasize a short-term, dose-limited approach, defining specific frequency and duration constraints.

For administration, the medicine is typically taken before meals because food is known to delay the absorption of Domperidone. The standard unit dose for adults and adolescents weighing 35 kg or more is 10 mg, administered up to three times daily. The total daily intake must not exceed 30 mg in a 24-hour period. Dosing frequency should be managed to maintain a suitable interval (e.g., eight hours) between administrations, while liquid suspensions require measurement using an accurate device.

A critical principle of use is the duration of treatment: Omidon must be used at the lowest effective dose for the shortest time possible, with treatment for acute symptoms not usually exceeding seven consecutive days. Furthermore, use is generally no longer licensed for children under 12 years or those weighing less than 35 kg.

Dosing requires adjustment for specific populations. For patients with severe renal impairment, the dosing frequency must be reduced (e.g., to once or twice daily). The use of the medicine is contraindicated in patients diagnosed with moderate or severe hepatic impairment. If a dose is missed, the standard protocol is to omit the missed dose and resume the regular schedule, strictly prohibiting doubling the intake.

Research Evidence / Overview of Studies for Omidon

Evidence for use in Relieving Nausea and Vomiting

Omidon was studied for the short-term relief of nausea and vomiting in adults and adolescents through randomized controlled trials (RCTs) and systematic reviews. This research explored how outcomes related to physical discomfort were monitored, specifically by measuring the time until vomiting stopped and changes in patient-reported outcomes describing perceived discomfort. The studies observed responses over defined time intervals, typically less than one week, and were relevant in trials assessing short-term or episodic symptom patterns.

Regulatory reviews cited data from trials that reported how symptoms evolved in the observed populations compared to cohorts receiving placebo over short observation periods. This evidence contributes to understanding symptom patterns but reflects the specific conditions under which these short-term studies were conducted.

Evidence for use in Upper Gastrointestinal Motility Disorders

Omidon was evaluated in studies focused on conditions characterized by fluctuating or episodic manifestations related to upper gastrointestinal motility disorders. The research examined specific outcomes related to the movement of food through the upper digestive tract. The main focus was to monitor outcomes reflecting daily functioning or activity level: objective measurements of the speed of stomach emptying and changes in specific patient-reported outcomes for symptoms like fullness and discomfort.

Evidence quality varies across studies for this indication. Sample sizes were modest in many trials, and the findings were mixed and demonstrated limited consistency across various research settings. Therefore, certainty remains low for the broad, general use of Omidon.

Research Gaps and Uncertainties

Several significant research limitation frames are noted in scientific and regulatory summaries. A major gap is the lack of research on long-term effects and outcomes related to continuous use; long-term effects are not fully established in the wider evidence base. Furthermore, data for certain groups remain insufficient. This includes a lack of robust, modern evidence for use in pediatric populations under 12 years, where the findings were mixed and evidence is limited.

Official Storage and Disposal Requirements for Omidon (Domperidone)

The storage and disposal of Omidon must strictly follow regulatory specifications to maintain product quality and safety.

Storage Conditions

Omidon must be stored at room temperature, generally defined as below 30 C (86 F). The medicine requires protection from light and moisture, and must be kept in its original container with the lid tightly closed. It is specifically stated that the product must not be refrigerated or frozen, as this can compromise certain formulations.

Disposal and Safety

It is a mandatory safety instruction to keep Omidon out of the sight and reach of children at all times. Any unused or outdated medicine must be disposed of according to local pharmaceutical waste regulations, and should not be discarded into household trash or wastewater.